As I mentioned previously, the rise could be due to an increase in fourth quarter sales numbers for Fanapt which would lead to a larger royalty check for Titan - and we'll know soon enough if that is actually the case - but with the latest Probuphine trial having completed full enrollment in September of last year, trial results should be forthcoming before the end of the second quarter.
Positive announcements on either front could lead to a continued run in the TTNP share price and also provide more ammo for the argument that Titan is a candidate for a partnership deal or acquisition.
It's worth adding on any dip back towards a buck, in my opinion, and let's watch the wires for the Q4 Fanapt sales numbers.
Disclosure: Long TTNP.
Originally posted on Tuesday at VFC's NEW Stock House.
No comments:
Post a Comment